Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 14:3:e27926.
doi: 10.4161/onci.27926. eCollection 2014.

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy

Yasmin Issa-Nummer  1 , Sibylle Loibl  1 , Gunter von Minckwitz  1 , Carsten Denkert  2
Affiliations

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy

Yasmin Issa-Nummer et al. Oncoimmunology. .

Abstract

We have prospectively validated in an independent clinical cohort the finding that elevated amounts of tumor-infiltrating lymphocytes in breast carcinoma tissues predict the response of patients to neoadjuvant chemotherapy. These results suggest that a robust tumor infiltration by T and B cells is a promising biomarker to define patients who might benefit from neoadjuvant chemotherapy.

Keywords: biological marker; breast cancer; neoadjuvant chemotherapy; response predictor.

PubMed Disclaimer

Figures

None
Figure 1. Predictive value of tumor-infiltrating lymphocytes in human breast carcinoma. The tumor-infiltrating lymphocytes (TILs) found in the neoplastic lesions of breast carcinoma patients comprise T and B cells. (A) Elevated amounts of TILs predict high rates of pathological complete response (pCR) to neoadjuvant chemotherapy. (B) In contrast, patients with tumors that contain low amounts of TILs exhibited low pCR rates in response to neoadjuvant chemotherapy.
See this image and copyright information in PMC

References

    1. von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31:3623–30. doi: 10.1200/JCO.2012.45.0940. - DOI - PubMed
    1. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456–66. doi: 10.1200/JCO.20.6.1456. - DOI - PubMed
    1. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105–13. doi: 10.1200/JCO.2009.23.7370. - DOI - PubMed
    1. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer - a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8:e79775. doi: 10.1371/journal.pone.0079775. - DOI - PMC - PubMed
    1. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8:151–60. doi: 10.1038/nrclinonc.2010.223. - DOI - PubMed

LinkOut - more resources